Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2017; 71(1): 36–39. doi:10.14735/amgh201736.

Ustekinumab – a new biologic drug for the treatment of Crohn’s disease

Milan Lukáš Orcid.org  1

+ Affiliation


To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Literature

1. Feagan BG, Sandborn WJ, Gasink C et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016; 375 (20): 1946–1960.
2. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of ustekinumab a human interleukin 12/23 monoclonal antibody in patients with moderate to severe Crohn’s disease. Gastroenterology 2008; 135 (4): 1130–1141. doi: 10.1053/j.gastro.2008.07.014.
3. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease.  N Engl J Med 2012; 367 (16): 1519–1528. doi: 10.1056/NEJMoa1203572.
4. Battat R, Kopylov U, Bessissow T et al. Association of ustekinumab trough concentration with clinical, biochemical and endoscopic outcome. Presented at: 11th Congress of ECCO, Amsterdam 2016.
5. Verstockt B, Van Assche G, Vermiere S et al. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. Expert Opin Biol Ther 2017; 17 (1): 31–47.
6. Deepak P, Loftus EV Jr. Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy. Drug Des Devel Ther 2016; 10: 3685–3698.
7. Rutgeerts P, Gasink C, Blank M et al. A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12/23p40 monoclonal antibody, in moderate-severe Crohn’s disease refractory to anti-TNFα: UNITI-1. Presented at: 11th Congress of ECCO, Amsterdam 2016.
8. Feagan B, Gasink C, Lang Y et al. A multicenter, randomized, double-blind, placebo-controlled phase 3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn’s disease who are naive or not refractory to anti-TNFα: results from the UNITI-2 study. Presented at: ACG 2015.
9. Sandborn W, Feagan BG, Gasink C et al. A phase 3 randomized, multicenter, double-blind, placebo-controlled study of ustekinumab maintenance therapy in moderate – severe Crohn’s disease patients: results from IM-UNITI. Gastroenterology 2016; 150 (4 Suppl 1): S157–S158. Abstract 768.

Credited self-teaching test